TCGA-AC-A8OP-01A-11R-A36F-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 20
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.270
- TNFA_SIGNALING_VIA_NFKB+0.250
- HEDGEHOG_SIGNALING+0.200
- WNT_BETA_CATENIN_SIGNALING+0.180
- NOTCH_SIGNALING+0.160
- APICAL_SURFACE+0.130
- HEME_METABOLISM+0.080
- ESTROGEN_RESPONSE_EARLY+0.070
- XENOBIOTIC_METABOLISM+0.050
- BILE_ACID_METABOLISM+0.040
Top 10 suppressed
- E2F_TARGETS-0.490
- MYC_TARGETS_V1-0.420
- G2M_CHECKPOINT-0.340
- OXIDATIVE_PHOSPHORYLATION-0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.340
- MTORC1_SIGNALING-0.320
- INTERFERON_ALPHA_RESPONSE-0.300
- PANCREAS_BETA_CELLS-0.300
- ALLOGRAFT_REJECTION-0.290
- GLYCOLYSIS-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-D8-A4Z1-01A-21R-A266-07 | — | A | 0.847 |
| 2 | TCGA-D8-A3Z5-01A-41R-A24H-07 | — | A | 0.811 |
| 3 | TCGA-D8-A145-01A-11R-A115-07 | — | A | 0.809 |
| 4 | TCGA-OL-A5RV-01A-12R-A28M-07 | — | A | 0.805 |
| 5 | TCGA-BH-A0E9-01B-11R-A115-07 | — | A | 0.796 |
| 6 | SRR1313116 | — | A | 0.793 |
| 7 | ERR2208935 | — | — | 0.790 |
| 8 | MBCProject_5774_T2_RNA | — | A | 0.789 |
| 9 | s0122235 | — | — | 0.781 |
| 10 | MBCProject_0771_T1_RNA | — | A | 0.779 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.270 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.250 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.180 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.160 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.070 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.050 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.020 | Remibrutinib | — uncovered |